Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in pediatric subjects with moderate to severe ulcerative colitis
2013-003032-77Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in autoimmune colitis (2 arms), sponsored by AbbVie Inc. Primary endpoint: Clinical remission at Week 8 by Pediatric Ulcerative Colitis Activity Index Partial Mayo Score (PMS). Started Dec 2013; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-003032-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003032-77.